Solbinsiran vs SYH2070

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atherosclerotic Cardiovascular Disease

Shared mechanism: ANGPTL3 · full Atherosclerotic Cardiovascular Disease pipeline

Solbinsiran

Developed by Eli Lilly

Phase 2 in Atherosclerotic Cardiovascular DiseaseRNAi (siRNA)
Partial signal

NCT05256654 · Phase 2 · completed

The study randomized 205 participants to three solbinsiran doses or placebo and masked both participants and investigators. Its primary endpoint was a laboratory biomarker rather than a hard clinical outcome, and the ApoB comparison was mixed across doses: significant for 400 mg but not for 100 mg or 800 mg, supporting moderate evidence rather than the highest grade.

Next expected readout: March 2027 · NCT07269210 (registry estimate)

Reported efficacy

Percent Change From Baseline for Apolipoprotein B (ApoB) at Day 180 (Baseline, Day 180): Percent Change From Baseline for Apolipoprotein B (ApoB) at Day 180 (Baseline, Day 180): LY3561774 100 mg -14.1% (Standard Error 4.98) | LY3561774 400 mg -24.3% (Standard Error 3.1) | LY3561774 800 mg -19% (Standard Error 3.35) vs Placebo -11.6% (Standard Error 3.65) (mixed)

Result source: NCT05256654

SYH2070

Developed by CSPC Pharmaceutical Group

Phase 2 in Atherosclerotic Cardiovascular DiseaseRNAi (siRNA)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: April 2027 · NCT07695597 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Atherosclerotic Cardiovascular Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointSolbinsiranSYH2070
LDL-C, % change-17.5% vs -12.7%−4.8 vs placebo800 mg · wk 38.6 · n 59NCT05256654
5 other results
  • -19.7% vs -8.7% 800 mg · wk 25.7 · n 59 · Phase 2 · secondary NCT05256654
  • -21% vs -12.7% 400 mg · wk 38.6 · n 58 · Phase 2 · secondary NCT05256654
  • -24% vs -8.7% 400 mg · wk 25.7 · n 58 · Phase 2 · secondary NCT05256654
  • -7.1% vs -12.7% 100 mg · wk 38.6 · n 30 · Phase 2 · secondary NCT05256654
  • -9.9% vs -8.7% 100 mg · wk 25.7 · n 30 · Phase 2 · secondary NCT05256654
—Not reported
Non-HDL-C, % change-27.3% vs -9.8%−17.5 vs placebo800 mg · wk 38.6 · n 59NCT05256654
5 other results
  • -31.5% vs -10.2% 800 mg · wk 25.7 · n 59 · Phase 2 · secondary NCT05256654
  • -27.6% vs -9.8% 400 mg · wk 38.6 · n 58 · Phase 2 · secondary NCT05256654
  • -33.1% vs -10.2% 400 mg · wk 25.7 · n 58 · Phase 2 · secondary NCT05256654
  • -13.5% vs -9.8% 100 mg · wk 38.6 · n 30 · Phase 2 · secondary NCT05256654
  • -19.8% vs -10.2% 100 mg · wk 25.7 · n 30 · Phase 2 · secondary NCT05256654
—Not reported
ApoB, % change-19% vs -11.6%−7.4 vs placebo800 mg · wk 25.7 · n 59NCT05256654
5 other results
  • -24.3% vs -11.6% 400 mg · wk 25.7 · n 58 · Phase 2 · primary NCT05256654
  • -14.1% vs -11.6% 100 mg · wk 25.7 · n 30 · Phase 2 · primary NCT05256654
  • -19.4% vs -9.5% 800 mg · wk 38.6 · n 59 · Phase 2 · secondary NCT05256654
  • -19.7% vs -9.5% 400 mg · wk 38.6 · n 58 · Phase 2 · secondary NCT05256654
  • -19.2% vs -9.5% 100 mg · wk 38.6 · n 30 · Phase 2 · secondary NCT05256654
—Not reported
Lp(a), % change—Not reported—Not reported
3-point MACE (% with event)—Not reported—Not reported

LDL-C, % change

Solbinsiran
-17.5% vs -12.7%−4.8 vs placebo800 mg · wk 38.6 · n 59NCT05256654
5 other results
  • -19.7% vs -8.7% 800 mg · wk 25.7 · n 59 · Phase 2 · secondary NCT05256654
  • -21% vs -12.7% 400 mg · wk 38.6 · n 58 · Phase 2 · secondary NCT05256654
  • -24% vs -8.7% 400 mg · wk 25.7 · n 58 · Phase 2 · secondary NCT05256654
  • -7.1% vs -12.7% 100 mg · wk 38.6 · n 30 · Phase 2 · secondary NCT05256654
  • -9.9% vs -8.7% 100 mg · wk 25.7 · n 30 · Phase 2 · secondary NCT05256654
SYH2070
—Not reported

Non-HDL-C, % change

Solbinsiran
-27.3% vs -9.8%−17.5 vs placebo800 mg · wk 38.6 · n 59NCT05256654
5 other results
  • -31.5% vs -10.2% 800 mg · wk 25.7 · n 59 · Phase 2 · secondary NCT05256654
  • -27.6% vs -9.8% 400 mg · wk 38.6 · n 58 · Phase 2 · secondary NCT05256654
  • -33.1% vs -10.2% 400 mg · wk 25.7 · n 58 · Phase 2 · secondary NCT05256654
  • -13.5% vs -9.8% 100 mg · wk 38.6 · n 30 · Phase 2 · secondary NCT05256654
  • -19.8% vs -10.2% 100 mg · wk 25.7 · n 30 · Phase 2 · secondary NCT05256654
SYH2070
—Not reported

ApoB, % change

Solbinsiran
-19% vs -11.6%−7.4 vs placebo800 mg · wk 25.7 · n 59NCT05256654
5 other results
  • -24.3% vs -11.6% 400 mg · wk 25.7 · n 58 · Phase 2 · primary NCT05256654
  • -14.1% vs -11.6% 100 mg · wk 25.7 · n 30 · Phase 2 · primary NCT05256654
  • -19.4% vs -9.5% 800 mg · wk 38.6 · n 59 · Phase 2 · secondary NCT05256654
  • -19.7% vs -9.5% 400 mg · wk 38.6 · n 58 · Phase 2 · secondary NCT05256654
  • -19.2% vs -9.5% 100 mg · wk 38.6 · n 30 · Phase 2 · secondary NCT05256654
SYH2070
—Not reported

Lp(a), % change

Solbinsiran
—Not reported
SYH2070
—Not reported

3-point MACE (% with event)

Solbinsiran
—Not reported
SYH2070
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

SYH2070: no structured comparison results are available for Atherosclerotic Cardiovascular Disease.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Solbinsiran: 4 of 4 rows · SYH2070: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricSolbinsiran
Dropout rate
8.5%800 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
show 2 more results
5.2%400 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
10%100 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
Discontinued due to AEs
0%800 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
show 2 more results
1.7%400 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
0%100 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
Serious AEs
3.4%800 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
show 2 more results
5.2%400 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
3.3%100 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
Most frequent reported AEs
800 mg
covid-19 3.4% (placebo 7%)
hypertension 3.4% (placebo 3.5%)
influenza 3.4% (placebo 0%)
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
show 2 more results
400 mg
covid-19 5.2% (placebo 7%)
injection site reaction 5.2% (placebo 0%)
nasopharyngitis 5.2% (placebo 5.3%)
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
100 mg
covid-19 13.3% (placebo 7%)
gastroenteritis 10% (placebo 5.3%)
hypertension 6.7% (placebo 3.5%)
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Solbinsiran

Apo B -19% (n=59) vs -11.6% (n=57) placebo @ 25.7wk800 mg
percent change · % of baseline
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
show 5 more results
-19.4% (n=59) vs -9.5% (n=57) placebo @ 38.6wk800 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
-24.3% (n=58) vs -11.6% (n=57) placebo @ 25.7wk400 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
-19.7% (n=58) vs -9.5% (n=57) placebo @ 38.6wk400 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
-14.1% (n=30) vs -11.6% (n=57) placebo @ 25.7wk100 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
-19.2% (n=30) vs -9.5% (n=57) placebo @ 38.6wk100 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
LDL-C -19.7% (n=59) vs -8.7% (n=57) placebo @ 25.7wk800 mg
percent change · % of baseline
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
show 5 more results
-17.5% (n=59) vs -12.7% (n=57) placebo @ 38.6wk800 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
-24% (n=58) vs -8.7% (n=57) placebo @ 25.7wk400 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
-21% (n=58) vs -12.7% (n=57) placebo @ 38.6wk400 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
-9.9% (n=30) vs -8.7% (n=57) placebo @ 25.7wk100 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
-7.1% (n=30) vs -12.7% (n=57) placebo @ 38.6wk100 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
HDL-C -19.4% (n=59) vs 4.3% (n=57) placebo @ 25.7wk800 mg
percent change · % of baseline
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
show 5 more results
-10.9% (n=59) vs 1.5% (n=57) placebo @ 38.6wk800 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
-12.8% (n=58) vs 4.3% (n=57) placebo @ 25.7wk400 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
-7.3% (n=58) vs 1.5% (n=57) placebo @ 38.6wk400 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
-2.1% (n=30) vs 4.3% (n=57) placebo @ 25.7wk100 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
-1.9% (n=30) vs 1.5% (n=57) placebo @ 38.6wk100 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
Non-HDL-C -31.5% (n=59) vs -10.2% (n=57) placebo @ 25.7wk800 mg
percent change · % of baseline
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
show 5 more results
-27.3% (n=59) vs -9.8% (n=57) placebo @ 38.6wk800 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
-33.1% (n=58) vs -10.2% (n=57) placebo @ 25.7wk400 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
-27.6% (n=58) vs -9.8% (n=57) placebo @ 38.6wk400 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
-19.8% (n=30) vs -10.2% (n=57) placebo @ 25.7wk100 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
-13.5% (n=30) vs -9.8% (n=57) placebo @ 38.6wk100 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
Triglycerides -59.7% (n=59) vs -15.1% (n=57) placebo @ 25.7wk800 mg
percent change · % of baseline
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
show 5 more results
-52.5% (n=59) vs -13.9% (n=57) placebo @ 38.6wk800 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
-57.8% (n=58) vs -15.1% (n=57) placebo @ 25.7wk400 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
-50.5% (n=58) vs -13.9% (n=57) placebo @ 38.6wk400 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
-45.9% (n=30) vs -15.1% (n=57) placebo @ 25.7wk100 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2
-38.3% (n=30) vs -13.9% (n=57) placebo @ 38.6wk100 mg
NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Solbinsiran's landscape · SYH2070's landscape